Salma Jabbour, MD, Professor and Vice Chair of Radiation Oncology at Rutgers Cancer Institute, provides an invaluable perspective rooted in her extensive experience and passion for radiation oncology, then she delves into the transformative changes witnessed in radiation oncology over the past two decades, contrasting its trajectory with precision oncology.
She shares compelling insights into the PROSPECT trial’s innovative approach of omitting radiation therapy entirely for rectal cancer patients, emphasizing the “impressive” results unveiled in the study. Then, the New York Times articles characterizing radiation as “brutal” for patients in this context is considered, and Dr. Jabbour navigates the complexities, challenges, and potential paradigm shifts these findings might signal for the field.
Don’t miss this unique episode and as always, please share with others after you hit the subscribe and like buttons. Check out also my book “Toxic Exposure” available everywhere.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
